-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $56 Price Target

Benzinga·10/12/2026 11:34:56
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:MLYS) with a Buy and maintains $56 price target.